These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. National survey of the ophthalmic use of anti-vascular endothelial growth factor drugs in Israel. Waisbourd M; Goldstein M; Loewenstein A Isr Med Assoc J; 2011 Mar; 13(3):141-6. PubMed ID: 21608333 [TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness. Brown G Curr Opin Ophthalmol; 2008 May; 19(3):175-6. PubMed ID: 18408489 [No Abstract] [Full Text] [Related]
8. Systemic bevacizumab treatment of a juxtapapillary retinal haemangioma. von Buelow M; Pape S; Hoerauf H Acta Ophthalmol Scand; 2007 Feb; 85(1):114-6. PubMed ID: 17244223 [No Abstract] [Full Text] [Related]
9. Juxtafoveal telangiectasias. Querques G; Delle Noci N Ophthalmology; 2008 Sep; 115(9):1636; author reply 1636. PubMed ID: 18762079 [No Abstract] [Full Text] [Related]
10. The effect of treatments given to patients before initiation of anti-vascular endothelial growth factor treatment. Hedaya J; Freeman WR Retina; 2008 Jun; 28(6):911-2; author reply 912. PubMed ID: 18536615 [No Abstract] [Full Text] [Related]
12. Bevacizumab: one treatment for all the seasons? Gelibter AJ; Di Segni S; Zeuli M; Cognetti F J Clin Oncol; 2008 Jan; 26(3):511; author reply 511-2. PubMed ID: 18202430 [No Abstract] [Full Text] [Related]